Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors

Arian Mansur 1, Tushar Garg 2, Apurva Shrigiriwar 3, Vahid Etezadi 4, Christos Georgiades 2, Peiman Habibollahi 5, Timothy C. Huber 6, Juan C. Camacho 7,8, Sherif G. Nour 9, Alan Alper Sag 10, John David Prologo 11 and Nariman Nezami 4,12,*

1 Harvard Medical School, Boston, MA 02115, USA; arianmansur@hms.harvard.edu
2 Division of Vascular and Interventional Radiology, Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, MD 21287, USA; tgang3@jhmi.edu (T.G.); cgeorgi@jhmi.edu (C.G.)
3 Division of Gastroenterology and Hepatology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA; ashrigi1@jhmi.edu
4 Division of Vascular and Interventional Radiology, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA; vahid.etezadi@umm.edu
5 Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; phabibollahi@mdanderson.org
6 Vascular and Interventional Radiology, Dotter Department of Interventional Radiology, Oregon Health and Science University, Portland, OR 97239, USA; huberti@ohsu.org
7 Department of Clinical Sciences, College of Medicine, Florida State University, Tallahassee, FL 32306, USA; juan.camacho@radpartners.com
8 Vascular and Interventional Radiology, Radiology Associates of Florida, Sarasota, FL 34239, USA
9 Department of Radiology and Medical Imaging, Florida State University College of Medicine, Gainesville, FL 32610, USA; sherif.g.nour@gmail.com
10 Division of Vascular and Interventional Radiology, Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA; alan.sag@duke.edu
11 Division of Vascular and Interventional Radiology, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA; john.david.prologo@emory.edu
12 Experimental Therapeutics Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA
* Correspondence: dr.nezami@gmail.com or nariman.nezami@umm.edu

Abstract: Image-guided percutaneous ablation methods have been further developed during the recent two decades and have transformed the minimally invasive and precision features of treatment options targeting primary and metastatic tumors. They work by percutaneously introducing applicators to precisely destroy a tumor and offer much lower risks than conventional methods. There are usually shorter recovery periods, less bleeding, and more preservation of organ parenchyma, expanding the treatment options of patients with cancer who may not be eligible for resection. Image-guided ablation techniques are currently utilized for the treatment of primary and metastatic tumors in various organs including the liver, pancreas, kidneys, thyroid and parathyroid, prostate, lung, bone, and soft tissue. This article provides a brief review of the various imaging modalities and available ablation techniques and discusses their applications and associated complications in various organs.

Keywords: ablation; image-guidance; primary; metastatic; tumors

1. Introduction

Image-guided percutaneous ablation is defined as the process of percutaneously introducing needlelike applicators to destroy or shrink tumors in a controlled and targeted fashion under image guidance. This approach is a well-established minimally invasive practice for primary and metastatic tumors [1,2]. The advent of image-guided percutaneous ablation along with transarterial therapies has allowed interventional radiologists to not
only be involved in the diagnosis of cancer but also serve as key players in its treatment and follow-up care [3]. Imaging modalities to guide ablation probes range from ultrasound (US) to magnetic resonance imaging (MRI), and ablation modalities can be divided into several types depending on the form of energy delivery and tissue injury [4]. Given the imaging of cancerous tissues and the damage to the tissue architecture with ablation, this work is applicable to other fields, both within and outside of medicine, that employ deformational analysis [5–7]. This article reviews the current role of image-guided percutaneous ablation modalities in the treatment of malignancies in different organs.

2. Imaging Modalities for Guiding Percutaneous Ablation Devices

Imaging plays critical roles in the pretreatment diagnosis and monitoring of tumors, peri-treatment placement of the ablation probe, guiding chemical or energy deposition during the procedure, and post-treatment assessment of outcomes [8]. Therefore, the selection of a proper imaging modality is critical for successful ablation. US and computerized tomography (CT) are most commonly employed [9].

2.1. Ultrasound

US is one of the most readily available imaging modalities used for guiding percutaneous ablation devices. It is relatively easy to operate, does not impart ionizing radiation, and provides real-time, multiplanar guidance at a low cost [10,11]. However, the use of US is limited by significant operator dependency, difficulty targeting deep structures in patients with obesity, limited visualization of air containing organs (e.g., intestinal loops), and limited utility for the visualization of tumors such as hepatic or iso-echoic renal tumors [9–13]. Contrast-enhanced ultrasound (CEUS), in which microbubble contrast agents are used as acoustic enhancers, is an alternative modality that enhances procedure guidance and pre- and post-procedural evaluation [14,15]. While CEUS can enhance the visibility of small tumors at a relatively low-cost, it cannot detect all lesions (e.g., deeply seated lesions in the hepatic dome), requires specific operator experience, is limited by the number of contrast injections during each session, and is not widely available [10,16].

2.2. Fluoroscopy

Fluoroscopy is an imaging technique that employs the use of X-ray pulses to capture real-time moving images [17]. Fluoroscopy was the main imaging technique for percutaneous biopsies and drainage procedures before the advent of CT that slowly replaced its use [18]. While useful for providing real-time feedback, fluoroscopy is restricted by its limited ability to navigate out of its plane and the exposure to radiation to both the patient and operator [17].

2.3. Computed Tomography, Cone-Beam CT, and CT Fluoroscopy

CT is the most commonly used imaging modality to guide percutaneous ablation devices as it is widely accessible, has a wide field of view, and is not limited by bowel gas [19]. It is commonly used without contrast; however a limited dose of contrast may be administered to visualize the lesion or identify critical vital structures to avoid non-target injury. The primary disadvantages of CT are ionizing radiation, single plane acquisition (though newer technologies such as IMACTIS CT-Navigation™ System (Hinckley, UK) by BVM Medical, Hinckley, UK are simulating and providing multiplanar views), and limited real-time visualization of iso-dense targets, and requires caution with the use of contrast media in patients with renal insufficiency [9]. Cone-beam computerized tomography (CBCT) is another modality that is well-suited to provide high spatial resolution and 3D image reconstructions. However, CBCT is limited by the relatively longer acquisition time than conventional CT, which can introduce motion artifacts [17]. Fluoroscopy guidance can be paired with CT to provide real-time feedback. It can allow for faster procedural times and improve targeting accuracy by avoiding errors due to patients’ movement and breathing [17]. However, this technique provides
a relatively high amount of radiation exposure to both the patient and operator [17]. Other ways to guide percutaneous ablation devices is through the use of lipiodol or radiopaque beads. These are sometimes used in transarterial chemoembolization and can enhance intraprocedural imaging guidance by their ability to be visualized with fluoroscopy or CT [20,21]. Other ways to guide percutaneous ablation devices is via pre-ablation embolization of lesions using lipiodol or radiopaque beads. These are used in transarterial chemoembolization and can enhance intraprocedural imaging guidance by their ability to be visualized by fluoroscopy or CT [20,21].

2.4. MRI

Magnetic resonance imaging (MRI) is less frequently used than US or CT but is useful in that it uses no ionizing radiation, provides a high contrast resolution between soft tissues, displays small tumors with increased sensitivity, allows for imaging in any orientation and on any plane, monitors thermal effects, and can be combined with diffusion-weighted imaging or MRI contrast agents to visualize more difficult lesions [11]. The primary advantage of MRI guidance for tumor ablation, however, lies in its unique thermal sensitivity that allows online monitoring of the progress of ablation. The main disadvantages of MRI use include the lack of MR compatible tools, closed MRI not having real-time guidance, a relatively complicated operation, susceptibility to artifacts, and high cost [11].

3. Physics and Mechanism of Action of Percutaneous Ablation Devices

Ablation modalities can be subdivided into thermal and non-thermal based modalities. Thermal ablation modalities include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and laser ablation. Non-thermal ablation modalities include chemical ablation (ethanol and acetic acid ablation), irreversible electroporation (IRE), and external energy delivery modalities (high intensity focused ultrasound (HIFU) and histotripsy (Figure 1). The advantages and disadvantages of the common ablation techniques are summarized in Table 1.

![Figure 1. Flowchart of ablation modalities. Ablation modalities can be subdivided into thermal and non-thermal based modalities. Thermal ablation modalities include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and laser ablation. Non-thermal ablation modalities include chemical ablation (ethanol and acetic acid ablation), irreversible electroporation (IRE), and external energy delivery modalities (high intensity focused ultrasound (HIFU) and histotripsy).](Image)

| Ablation Device | Advantages | Disadvantages |
|----------------|------------|---------------|
| Ethanol        | Cheap      | Non-uniform intertumoral distribution |
|                | Fast and simple | More recurrence |
|                | Well-tolerated | Multiple treatments often required |

Table 1. The advantages and disadvantages of the common ablation techniques.
Table 1. Cont.

| Ablation Device | Advantages                                                                 | Disadvantages                                                                 |
|-----------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| RFA             | • Less expensive than other modalities                                        | • Ablation zone not visible while ablating                                      |
|                 | • Various electrode shapes                                                   | • Pacemaker interference                                                       |
|                 | • Most-studied                                                              | • Painful (higher need for general anesthesia)                                  |
|                 | • Widely available                                                          | • Heat sink effect                                                             |
|                 |                                                                             | • Requires grounding pads (Monopolar)                                          |
|                 |                                                                             | • Limited ablation zone                                                        |
| Cryoablation    | • Ablation zone visible while ablating                                       | • Inconsistent ablation sizes                                                  |
|                 | • No pacemaker interference                                                  | • Some heat pump effect                                                        |
|                 | • Iceball visualization during CT, MR and US guidance                        | • Long ablation times                                                          |
|                 |                                                                             | • Higher risk of bleeding                                                      |
|                 |                                                                             | • Cryoshock possibility                                                        |
| MWA             | • High temperatures (>150 °C)                                               | • Usually performed under general anesthesia                                   |
|                 | • Large ablation zones                                                      | • More difficult than RFA                                                      |
|                 | • Does not require grounding pads                                           | • Not as efficient in larger tumors                                            |
|                 | • Less heat sink effect than RFA                                             |                                                                                |
|                 | • Short ablation times                                                       |                                                                                |
|                 | • Can utilize multiple antenna probes in proximity                           |                                                                                |
| Laser           | • Precise and efficient targeting                                           | • Limited energy penetration                                                   |
|                 | • Reduced image artifacts given lack of metal and small diameter of applicator | • Small ablation zones (1–2 cm in diameter)                                    |
| IRE             | • Short ablation times                                                       | • Requires general anesthesia with paralytic agents                            |
|                 | • Well-defined ablation zones                                               | • Risk of cardiac arrhythmias                                                  |
|                 | • Adjacent tissue architecture preserved                                     | • Challenging probe placement geometry                                          |
|                 | • No heat sink effect                                                        |                                                                                |
| HIFU            | • Non-ionizing                                                              | • Requires patients to be still                                                |
|                 | • Non-invasive                                                              | • Near-field heating                                                           |
|                 | • Extracorporeal                                                            | • Long treatment times                                                         |
|                 |                                                                             | • Can lead to skin side-effects                                                |
| Histotripsy     | • Non-ionizing and non-thermal                                              | • Not widely available                                                         |
|                 | • Can destroy tissue noninvasively                                           | • Low cavitation threshold in gas-containing organs makes it less suitable    |
|                 | • Small scars                                                               | • Not ideal for tumors within large tissue depth                               |
|                 | • No heat sink effect                                                        | • May induce thrombosis                                                        |
|                 | • Tissue selectivity                                                        |                                                                                |
|                 | • Well-demarcated boundaries                                                |                                                                                |
|                 | • Real-time feedback                                                        |                                                                                |

3.1. Radiofrequency Ablation

RFA (Figure 2) works by delivering radiofrequency waves in the 375–500 kHz range to an area surrounding a generator-coupled electrode, causing an oscillating electric field that creates frictional energy by electron collision. This collision generates heat that leads to eventual tumor destruction by coagulation necrosis from temperatures above 60 °C [19,24,25].
Diagnostics 2022, 12, x FOR PEER REVIEW 5 of 35

(A) (B)

Figure 2. Schematic presentation of radiofrequency ablation. (A) Design of a bipolar RFA system, in which electrical current is delivered through an electrode that functions as both anode and cathode [26]; bi-polar electrodes obviate the need for grounding pads; (B) Representative example of RFA used to target a lesion in right middle lobe of a lung.

3.2. Microwave Ablation

MWA (Figure 3) uses microwave energy in the 300–3000 MHz range from an antenna, creating oscillation of ions in the target [19]. This oscillation creates heat and results in coagulative necrosis. This technique allows for faster ablation times, larger ablation zones, and a reduced heat sink effect compared to RFA [27,28].

(A) (B)

Figure 3. Schematic presentation of microwave ablation. (A) Design of a microwave antenna that generates an oscillating electromagnetic field, leading to the continuous realignment of molecules with an intrinsic dipole moment (mostly water) [26]; (B) Representative example of MWA used to target a liver tumor.

3.3. Cryoablation

Cryoablation (Figure 4) destroys tumors by applying freezing temperatures or alternating freeze–thaw cycles [29]. This technique works by utilizing the Joule–Thomson effect by which certain gases such as nitrogen, nitrous oxide, or argon drop in temperature when going from high pressure to low pressure [24,30]. Once the target region reaches temperature of −40 °C, ice crystals form in the extracellular space that leads to increased tonicity and osmotic damage to cells in the area [24,31,32]. Eventually, intracellular ice forms, rupturing the plasma and organelle membranes, followed by indirect cell death by thrombosis of damaged blood vessels that lead to ischemia and inflammation [24,33].
Figure 4. Schematic presentation of cryoablation. (A) Design of a cryoprobe, whereby a cryogen circulates to rapidly cool the cryoprobe to −160 °C, resulting in an ice ball around the cryoprobe of varying temperatures, of which −20 °C is lethal [26]. Figure adapted from Nelson et al. [26]; (B) Representative example of cryoablation used to target a kidney tumor.

3.4. Irreversible Electroporation

IRE (Figure 5) is a nonthermal ablation modality that causes cell death through repeated short-duration high-voltage electrical pulses, leading to ruptured cellular membranes and irreversible cell death [34,35]. IRE differs from the thermal modalities in that it is not affected by the heat sink effect [1].

Figure 5. Schematic presentation of irreversible electroporation. (A) Two IRE probes are placed in parallel around the tumor, whereby multiple high-voltage electrical pulses are delivered to produce a uniform zone of ablation [26]; (B) Representative example of IRE used to target a pancreatic tumor.

3.5. Laser Ablation

Laser ablation uses light energy to precisely heat a tumor electromagnetically and cause coagulative necrosis. It is a flexible technique that can be conveniently coupled through optical fibers that are MR compatible, but the small ablation zones require multiple placements [19]. Furthermore, laser ablation can have limited energy penetration as most body tissues absorb and scatter light [36].
3.6. High-Intensity Frequency Ultrasound

HIFU (Figure 6) is a noninvasive thermal ablation technique that causes coagulation necrosis by delivering high-intensity ultrasound waves onto a focal area [37]. The sources of ultrasound are often placed extracorporeally or rectally without the need for the transcutaneous insertion of probes.

Figure 6. Schematic presentation of high-intensity frequency ultrasound for ablation of a prostate tumor. The extracorporeal transducer generates high-intensity ultrasound to carry and propagate energy onto a focused area deep within tissue media. Temperatures are raised to a level that is sufficient for thermotherapeutic effects, resulting in coagulation necrosis [38,39].

3.7. Histotripsy

Histotripsy (Figure 7) is a noninvasive ablation technique based on ultrasound but is nonthermal. It uses focused ultrasound waves to mechanically destroy tissue through cavitation, causing minimal damage to surrounding tissue [40]. It works by using pulsed sound waves to create “bubble clouds” from gases naturally occurring in the target. These bubbles form and collapse quickly, leading to mechanical force-based destruction of the tissue [41].

Figure 7. Schematic presentation of histotripsy for liver tumor ablation. Like HIFU, a focused transducer is used to generate and focus ultrasound to the tumor, but it instead causes mechanical damage without thermal coagulation via short, intense acoustic pulses that create dense energetic “bubble clouds” in the tissue media. These bubbles rapidly expand and collapse to mechanically disintegrate tissue [42].
4. Primary and Metastatic Liver Tumors

The preferred treatment option for localized hepatocellular carcinoma (HCC) is surgical resection. However, a proportion of patients are not candidates for surgery due to the extent of the tumor or underlying poor liver function [43]. Ablation for localized HCC is a viable treatment option in patients with nonresectable tumors who are not transplant candidates, especially in patients with no worse than Child-Turcotte-Pugh class A or B cirrhosis, or in transplant candidates as a form of bridging or downstaging therapy [44]. The 2022 Barcelona Clinic Liver Cancer guidelines now recommend ablation as the standard of treatment in patients with solitary HCC ≤ 2 cm without vascular invasion or extrahepatic spread, for which liver transplant is not feasible [45]. Multiple percutaneous ablation modalities are used in treating liver tumors with the main techniques being RFA and MWA. MWA has several theoretical advantages over RFA in that it can obtain shorter ablation times, multiple ablations can be performed simultaneously, it can reach higher intratumoral temperatures with larger ablation zones, its efficacy is not reduced by electrical impedance, and it is less susceptible to the heat sink effect [44,46–51]. However, these advantages may make MWA more dangerous in injuring nearby structures [44,51,52]. Several randomized trials have been conducted to compare MWA versus RFA for HCC treatment, showing that MWA is comparable to RFA for HCC treatment in terms of safety and efficacy but has reduced local tumor progression and shorter ablation times (Table 2) [13,51,53–59]. A case of a patient receiving MWA for a hepatic metastatic leiomyosarcoma in segment V is presented in Figure 8.

Figure 8. Microwave ablation of hepatic metastatic leiomyosarcoma. A 73-year-old female patient with a 2.1 × 1.5 cm sub-capsular metastatic leiomyosarcoma (white arrow) in segment V (A) on CT scan. The patient underwent chemotherapy followed by MWA. (B) Probe placement and (C) immediate post-ablation image of the right hepatic lobe lesion. The patient then underwent proton therapy of inferior vena cava mass and left hepatic metastasis. (D) Six-month follow-up MRI shows complete response.

Cryoablation can also be used in the treatment of HCC. While heat-based thermal ablation modalities are typically used in cirrhotic patients due to their lower rates of bleeding complications, cryoablation technology now includes thinner probes and helium–argon as a cryogen instead of liquid nitrogen [60–63]. Cryoablation is usually the preferred
modality for hepatic tumors near vulnerable structures as it can produce smaller ablation zones, which can be monitored in real-time via intraprocedural CT [63,64]. Furthermore, cryoablation allows for neurolysis, making it suitable for subcapsular lesions or lesions close to the diaphragm. While the data comparing cryoablation to RFA for HCC is not as extensive as that between MWA and RFA, a randomized controlled trial and large population-based retrospective study found non-inferior results for cryoablation [63,65,66].

IRE is another modality that can be used in treating liver tumors, especially when close to adjacent major blood vessels or biliary ducts, as it’s not subjected to the heat sink effect. Results from clinical trials, and meta-analysis showed that IRE was effective and relatively safe (Table 2) [67–72]. Figure 9 discusses the management of a patient with cirrhosis and HCC with both MWA and IRE.

Figure 9. Microwave ablation and irreversible electroporation of hepatocellular carcinoma. A 72-year-old male with alcohol-induced cirrhosis and HCC was found to have a 3.5 × 2.6 cm biopsy-proven HCC lesion (white arrow) in segment II (A), LI-RADS 4 lesion in segment VII, and LI-RADS 3 lesion in the caudate lobe on MRI. (B,C) The patient underwent percutaneous MWA of the segment II HCC. (D) Four-month follow-up MRI showed complete response of the segment II HCC to MWA, but the two previously noted lesions (E) in the caudate lobe and segment VII progressed to LI-RADS 5. The patient underwent image-guided percutaneous ablation of these two lesions two months later, receiving (F) NanoKnife IRE for segment II/caudate and (G) MWA for segment VII lesion. (H) One-month follow-up MRI shows no residual tumor. The patient was transplanted two months later.

HIFU has been shown to be safe and effective with comparable outcomes to the other modalities [73–78]. A prospective comparative study revealed that HIFU was as safe and effective as RFA [79]. The new #HOPE4LIVER clinical trial is currently in the process of seeking regulatory approval to determine the efficacy of histotripsy for both primary and metastatic liver tumors.

Percutaneous ethanol or acetic acid injections are also sometimes used in resource-limited settings but are not usually recommended if other modalities are available. However, the literature is inconsistent, and some studies show a comparable role of ethanol in small liver tumors [31,80,81].
Table 2. Comparison of ablation modalities for hepatocellular carcinoma.

| Authors                  | Study Design | Recruitment Years | Country      | Sample Size | Comparison | Cancer       | Residual Disease | LTR          | OS           | PFS          | Complications | Mean Ablation Time |
|--------------------------|--------------|-------------------|--------------|-------------|------------|--------------|-----------------|--------------|-------------|--------------|----------------|-------------------|
| Kamal et al. [13]        | RCT          | 2017              | Egypt        | 56          | MWA vs. RFA | ≤5 cm HCC    | 5.9% vs. 11.2%   | 9.1% vs. 9.1% | 82.1% vs. 78.6% | 92.3% vs. 90.9% | 7.1% vs. 0% (NSD) | 4.41 vs. 14.21 min (p < 0.001) |
| Shibata et al. [58]      | RCT          | 1999–2000         | Japan        | 72          | MWA vs. RFA | ≤4 cm HCC    | 11% vs. 4% (p = 0.26) | 17.4% vs. 8.3% (27 months, p = 0.03) | 86% vs. 84% (2-year p = 0.07) | N/A            | 11.4% vs. 2.8% (p = 0.002) | 2 vs. 52 min (p < 0.001) |
| Vietti et al. [55]       | RCT          | 2011–2015         | Switzerland  | 144         | MWA vs. RFA | ≤4 cm HCC    | 5% vs. 4% at 1 month (p = 0.93) | 6% vs. 12% (48 months, p = 0.27) | 86% vs. 84% (2-year p = 0.02) | N/A            | 2 vs. grade 4 in MWA vs. 5 grade 3 in RFA | 4 vs. 12 min |
| Abdelaziz et al. [51]    | RCT          | 2009–2014         | Egypt        | 111         | MWA vs. RFA | ≤5 cm HCC    | Complete ablations: 96.1% vs. 94.2% (p = 0.48) | 3.9% vs. 13.5% (48 months, p = 0.48) | 64% vs. 47.4% (2-year p = 0.49) | N/A            | 3.2% vs. 11.1% (minor, p = 0.017) | N/A |
| Yu et al. [54]           | RCT          | 2016              | China        | 203         | MWA vs. RFA | ≤5 cm HCC    | 31.5% vs. 33.4% (3-year, p = 0.91) | N/A            | N/A          | N/A          | 3.4% vs. 2.9% (major, p = 0.59) | 9 vs. 24.4 min (p < 0.001) |
| Chong et al. [50]        | RCT          | 2011–2017         | China        | 95          | MWA vs. RFA | ≤5 cm HCC    | 4.3% vs. 2.2% (1 month, p = 0.999) | N/A            | 72.7% vs. 67.1% (5-year p = 0.012) | DFS: 24.1% vs. 22.7% (overall, p = 0.099) | 2.1% vs. 2.2% (overall, p = 0.099) | 12 vs. 24 min (p < 0.001) |
| Wang et al. [54]         | RCT          | 2008–2013         | China        | 300         | Cryoablation vs. RFA | ≤4 cm HCC    | Effectiveness: 99.5% vs. 98.8% (p = 0.006) | 5.6% vs. 10% (p = 0.115) | 60% vs. 66% (5-year, NSD) | DFS: 34% vs. 30% (5-year, NSD) | 3.9% vs. 3.3% (major, p = 0.778) | N/A |
| Chen et al. [62]         | Retrospective population-based | 2004–2015 | United States | 3614        | Cryoablation vs. RFA | HCC        | N/A          | N/A          | NSD in CSS | N/A          | N/A          | N/A |
| Meijerink et al. [67]    | RCT          | 2014–2018         | Netherlands  | 51          | IRE        | CRLM ≤ 5 cm  | 84% achieved local tumor control after repeat procedure | 32% after 1 year | Median 2.7 years (95% Cl 1.1–3.8) | 68% (95% Cl 39, 84) | 40% adverse effects | Median procedure time 2.43 h w/o anesthesia | N/A |
| Frühling et al. [60]     | Nonrandomized clinical trial | 2011–2014 | Sweden       | 30          | IRE        | HCC and liver metastasis | 23.1% at 3 months and 34.2% at 6 months | 26.6% after both 3 and 6 months | 56.7% | N/A | 5.3% major, 20% minor, - |
| Glassberg et al. [83]    | Meta-analysis | 2009–2017 | N/A          | 28 studies | MWA vs. RFA | HCC and liver metastasis | N/A | LTP: RR = 0.70; p = 0.02 | N/A | N/A | N/A |

Abbreviations: RCT, randomized control trial; LTR, local tumor recurrence; OS, overall survival; PFS, progression-free survival; DFS, disease-free survival; CSS, cancer-specific survival; NSD, no significant difference; MC = Monte Carlo; RR, relative risk, LTP, local tumor progression; w/o, without; N/A, not applicable.
While ablation is generally accepted as a safe alternative for unresectable liver tumors, various complications may occur, with hemorrhage being one of the most common complications in patients treated with thermal ablation [84]. A systematic review of 15,744 patients found that mortality ranged from 0% to 0.88% with a pooled morality of 0.15% for RFA and 0.23% for MWA [85]. Major complication rates were 4.1% for RFA and 4.6% for MWA while minor complication rates were 5.9% for RFA and 5.7% for MWA [85]. Some of the common major complications noted were intraperitoneal hemorrhage, portal vein thrombosis, biloma, bile duct injury, and liver dysfunction [85]. With regard to cryoablation, there is a concern for an increased risk of bleeding due to the multiple cryoprobes without the ability to cauterize or coagulate vessels [84]. Furthermore, cryoablation runs the risk of cryoshock and parenchymal crack in the liver [84]. While IRE initially ran into the risk of cardiac toxicity and arrhythmias, the introduction of cardiac synchronization with IRE has made it a relatively safe choice for liver ablation [86]. Most of the complications of IRE are primarily due to electrode placement, and IRE appears to be safer than thermal ablation when adjacent to critical structures like the bile duct, as thermal ablation tends to lead to portal vein thrombosis, necrosis, and bilomas [86]. Moreover, most of the complications of IRE in liver ablation tend to be mild or transient, such as fever, local pain, abdominal distension, ascites, nausea, and vomiting [87]. In the case of HIFU, ablation of small liver tumors, even in patients with advanced cirrhosis, is relatively safe, but current challenges that are still being addressed are targeting tumors in difficult locations, such as the liver dome, structures near the rib cage, structures near large blood vessels or the heart, and structures adjacent to hollow viscera [88].

5. Renal Tumors

While the conventional treatment for renal cell carcinoma (RCC) has historically been radical nephrectomy, efforts to reduce the invasiveness, such as with nephron-sparing surgeries, have developed over the years [9,89-91]. This change to less invasive procedures to preserve the renal parenchyma has also led to use of image-guided thermal ablations for renal tumors with promising outcomes in unresectable tumors [36,92-96]. Current national comprehensive cancer network (NCCN) guidelines currently have ablative techniques as one of the primary treatment options for stage I-III kidney cancer [97].

A meta-analyses and multiple cohort studies have shown that RFA and cryoablation have comparable efficacy and safety profiles for renal masses [98-103]. However, cryoablation appears to have better outcomes in larger >3–4 cm tumors than RFA [103-106]. Figure 10 presents the use of cryoablation on a patient with a left renal mass. MWA has also been shown to result in promising outcomes in renal tumors. A retrospective analysis of T1N0M0 RCC showed that the outcome of CT-guided percutaneous MWA is comparable to RFA or cryoablation with regard to treatment response and is associated with less sedation and lower treatment times [107]. Several other studies have shown comparable therapeutic and renal function outcomes among MWA, RFA, and cryoablation (Table 3) [108,109]. Complications for renal tumor ablation include both injury to the kidney, as well as the surrounding structures, like the vasculature or urinary tract. Complications include hemorrhage, ureteral stricture, urine leakage, urinary tract infections, pneumothorax, nerve injury, skin burns, and needle tract seeding [110]. In a prospective study of 573 renal ablation procedures (254 RFA and 311 cryoablation) performed in 533 patients with 633 tumors, complications did not statistically differ between the two [101]. In the RFA group, 3.9% had nerve injury, 2.1% had ureteral stricture, and 1.2% had hemorrhage/vascular injury/anemia [101]. In the cryoablation group, 4.8% had hemorrhage/vascular injury/anemia, 2.6% had hematuria, 1% had pulmonary embolus, and 0.6% had nerve injury [101]. A retrospective study of 105 US-guided percutaneous MWA in 111 patients with renal tumors found a complication rate of 24.8% with major complications including two hydrothorax and one bowel injury, while the minor complications included microscopic hematuria, mild thermal injury to the psoas muscle, perirenal hematoma, diarrhea, abdominal distension, edema of the lower extremities, and thermal injury to the pelvicalyceal system [111]. Some ways to prevent complications
include holding anticoagulants to prevent bleeding, hydrodissection to avoid thermal injury to adjacent structure, and pyeloperfusion to protect the ureter [112,113].

Figure 10. Cryoablation of left renal mass. A 57-year-old male with hematuria and left flank pain was found to have a left renal enhancing lesion (white arrow) on MRI images (A). (B) CT-guided percutaneous core needle biopsy found the 2.0 × 1.8 cm right renal lesion to be medullary fibroma while the 2.1 × 2.2 cm left renal lesion was International Society of Urologic Pathologists (ISUP)/World Health Organization (WHO) grade 2 RCC. The patient underwent cryoablation of the left mass. (C) One-month follow-up MRI showed complete tumor response. (D) Six-month follow-up MRI showed lesion shrinkage without residual tumor.

Table 3. Comparison of ablation modalities for renal tumors.

| Authors            | Study Type          | Inclusion Years | Sample Size | Comparison                        | Cancer                  | Findings                                                                 |
|--------------------|---------------------|-----------------|-------------|-----------------------------------|-------------------------|--------------------------------------------------------------------------|
| Thompson et al. [98]| Retrospective cohort| 2000–2011       | 1803        | Partial nephrectomy (PN) vs. RFA vs. cryoablation | T1N0M0 RCC              | No significant difference in local recurrence-free survival. Metastases-free survival better in PN and cryoablation relative to RFA. |
| Atwell et al. [99]  | Retrospective review| 2000–2010       | 385         | Cryoablation vs. RFA              | RCC ≤ 3 cm              | No significant difference in complications, local tumor recurrence, and local recurrence-free survival. |
Table 3. Cont.

| Authors                  | Study Type | Inclusion Years | Sample Size | Comparison                          | Cancer          | Findings                                                                 |
|--------------------------|------------|-----------------|-------------|-------------------------------------|-----------------|--------------------------------------------------------------------------|
| El Dib et al. [100]      | Meta-analysis | 2000–2008      | 883         | Cryoablation vs. RFA                 | RCC             | No significant difference in complications and pooled proportion of clinical efficacy |
| Atwell et al. [101]      | Retrospective cohort | 2000–2010     | 533         | Cryoablation vs. RFA                 | RCC             | No significant difference in major complication rates.                   |
| Andrews et al. [102]     | Retrospective cohort | 2000–2011     | 1798        | PN vs. cryoablation vs. RFA          | T1N0M0          | No significant difference in survival and local recurrence, and metastases.|
| Zhou & Arellano [107]    | Retrospective cohort | 2006–2016     | 384         | MWA vs. RFA vs. cryoablation         | T1cN0M0 RCC     | Similar complication rates and immediate renal function changes. MWA had lowest ablation time, procedural time, and dosage of sedative. |
| Martin & Athreya [108]   | Meta-analysis | 2003–2012      | 3153        | Cryoablation vs. MWA                 | Small renal masses | No significant difference in primary effectiveness, cancer-specific survival, local tumor progression, and progression to metastatic disease. |
| Zhou et al. [109]        | Retrospective cohort | 2006–2016     | 297         | MWA vs. RFA vs. cryoablation         | T1aN0M0 RCC     | At 2 years follow-up, no significant difference in local recurrence, metastatic progression, stability of renal function, and adverse event rate. |

6. Pancreatic Tumors

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, and most patients are diagnosed with locally advanced or metastatic disease [114]. Current national guidelines recommend systemic therapy as the first-line treatment for unresectable pancreatic tumors [114]. However, most patients relapse, and chemotherapy is still associated with poor survival and complications [115]. Additionally, there are low rates of conversion surgery with R0 resections following systemic treatment [116]. Therefore, ablative techniques have emerged as an alternative adjuvant treatment for patients with pancreatic tumors, but they are mainly used as a consolidative treatment in stable tumors or as palliative care for tumors with persistent major vascular involvement [115,116]. The role of tumor ablation in pancreatic cancer is still understudied and there have been no completed trials that compare multiple ablation modalities [115,117]. Examples of the major ongoing trials are the “Pancreatic Locally Advanced Unresectable Cancer Ablation” (PELICAN) trial [118], which is an international multicentric superiority RCT investigating the effect of RFA in combination with chemotherapy in 228 patients across 16 centers in the Netherlands and four European centers, and the CROSSFIRE trial in the Netherlands, which compares the efficacy of IRE and chemotherapy (FOLFIRINOX) to the efficacy of FOLFIRINOX and stereotactic ablative radiotherapy (SABR) in 138 patients with non-resectable, non-metastasized, locally advanced pancreatic cancer (LAPC) [117].

The most used and studied ablative therapies for pancreatic cancer are RFA, IRE, and stereotactic body radiation therapy (SBRT) [117]. A recent systematic review screened 1037 articles published before 1 June 2014 and found 38 clinical studies with 1164 patients with LAPC, of which seven involved RFA, four involved IRE, 16 involved SBRT, five involved HIFU, two involved iodine-125, two involved iodine-125-cryosurgery, one involved photodynamic therapy, and one involved MWA [119]. The review found that all strategies seemed safe and feasible [119]. Of the modalities that had outcomes for postoperative-procedure-related morbidity and mortality, RFA had 4–22% and 0–11%, respectively, IRE had 9–15% and 0–4%, respectively, and SBRT had 0–25% and 0%, respectively [119]. Median survival for RFA, IRE, SBRT, and HIFU was 25.6, 20.2, 24.0, and 12.6 months, respectively [119]. Furthermore, the
study found that IRE procedures were safer when done with a percutaneous approach than with an open approach [119]. Figure 11 describes the case of a patient with locally advanced pancreatic cancer who was treated with IRE.

Figure 11. Irreversible electroporation of locally advanced pancreatic mass. A 57-year-old male with a history of pancreatic cancer presented with nonspecific epigastric pain. He was found to have locally advanced pancreatic head tumor (white arrow). He underwent chemotherapy and radiation and follow up CT and PET images (A–C) showed persistent locally advanced pancreatic head tumor. (D) He subsequently underwent IRE. (E) One-month follow up CT scan shows no residual disease.

Another review that examined ablation treatments for pancreatic cancer from January 2010 to May 2020, found 36 articles that met the inclusion criteria, of which 18 were for RFA, three for MWA, 11 for IRE, and four for electrochemotherapy (ECT) [115]. The mean (range) overall survival was 23 months (9–30), 24.9 months (4.9–85) and 11.5 months for RFA, IRE, and ECT, respectively [115]. The major and minor mean complication rate was 1.9% and 20.2% for RFA, respectively, 8.5% and 8.6% for MWA, respectively, 1.5% and 15% (open vs. 29% percutaneously) for IRE, respectively, and 0% and 23.1% for ECT, respectively [115].

The main risks of ablation in the pancreas are due to the location of the pancreas. Unlike other solid organs, the pancreas both involves and is surrounded by many medium-to-large-sized blood vessels such as the celiac and hepatic arteries, the portal vein, and the superior mesenteric and splenic vessels [120]. Common complications due to ablation include pancreatitis, pancreatic duct fistulas and leaks, and pseudocysts. For RFA, there appears to be a correlation between the temperature reached in the ablation and complications, which is why some authors suggest avoiding over 90 °C in ablation temperatures [121]. Common complications associated with RFA also tend to include pancreatic fistulas, portal thromboses, and pancreatitis [121]. While the data concerning MWA complications is more scarce, possible complications include mild pancreatitis, hyperamylasemia, pancreatic ascites, mild hemorrhage, and pseudocysts [121,122]. Possible complications for cryoablation include pancreatic and bile leak, gastrointestinal bleeding and obstruction, infection, and hemorrhage [122].

7. Primary and Metastatic Adrenal Tumors

While ablation has been primarily focused on treating malignancies in organs such as the liver and kidneys, ablation modalities have expanded to target both benign and malignant endocrine tumors, especially those of the thyroid, parathyroid, and adrenal
glands, to address systemic endocrinopathy [123]. Adrenal tumors have an estimated prevalence of 3–10% in those aged > 50 years and many are found as “incidentalomas” on abdominal imaging, for which most have no clinical significance [123–125]. Surgery remains the recommended treatment of choice for adrenal tumors that have clinical significance [123]. Ablation of these tumors is beginning to garner attention in both primary and metastatic settings due to its minimally invasive profile and its ability to be used in patients who are unfit for surgery. Furthermore, the expansion of ablation technology has allowed for further precision to target diseased tissue and preserve the adrenal parenchyma. This expansion can also be seen in new methods, such as the recent novel protocol of single-session CT-guided percutaneous MWA without pre-procedure adrenergic blockade that showed successful ablation, symptomatic improvement, and no residual tumor at 3-month follow-up in two patients with symptomatic Cushing syndrome who were not surgical candidates [126]. However, the data on clinical efficacy is still rather limited.

Most of the evidence of ablation therapy for adrenal tumors comes from small observational studies and case series that use RFA, MWA, and cryoablation. Figure 12 demonstrates a case of an adrenal tumor treated with cryoablation while still limited, the data is encouraging for ablation. In a recent review, Donlon and Dennedy found that unilateral aldosterone-producing adenomas (APA) and cortisol-secreting adenomas cured endocrinopathy with RFA and MWA for 75–100% of cases after a single ablation and 100% after repeated ablation [123]. They also found that thermal ablation leads to the promising resolution of hypertension following a thermal ablation for APA, similar to unilateral adrenalectomy [123]. Furthermore, this review also found promising results for RFA and MWA in metastatic adrenal tumors, in which the presence of residual tumor following ablation was seen in <25% of cases with <25% recurrence rates [123]. RFA has also shown to be promising in patients with severe adrenocorticotropic hormone (ACTH)-dependent Cushing syndrome for which bilateral adrenalectomy is not a suitable option [123,127]. A small case-series showed that all five patients who underwent bilateral RFA under CT-guidance had technical success with a resolution of their hypercortisolemia [127].

Figure 12. Cryoablation of adrenal tumor. (A) Axial CT image in an HCC patient with a single metastatic focus to the left adrenal (white arrow). (B) During cryoablation the entire mass (white arrow) demonstrates lowered HU as its density decreases during freezing. The “ice-ball” is difficult to visualize in fatty regions because its CT density is very close to that of fat. The peri-adrenal fat becomes “fuzzy” indicating extension of the “ice-ball” around the adrenal mass.
A recent 2021 meta-analysis studied the efficacy and safety of image-guided percutaneous ablation of adrenal metastases [128]. Of the 959 patients undergoing RFA, MWA, cryoablation, and ethanol injections, or some mixture of these modalities, they found a pooled 1-year local control rate of 80%, a pooled 1-year overall survival of 77%, an overall rate of severe adverse events (CTCAE grade 3 or higher) of 16.1%, and an overall rate of low-grade adverse events (CTCAE grade 2 or lower) of 32.6% [128].

Ablation also shows promise in metastatic pheochromocytomas and paragangliomas (PPGLI), which are neuroendocrine tumors [129]. A retrospective analysis performed at the Mayo Clinic analyzed 31 patients with metastatic PPGL and 123 lesions, 42 of which were treated with RFA, 23 with cryoablation, and four with PEI, from 1999 to 2017 [129]. Radiographic local control was obtained in 86% of lesions and 92% of the procedures led to improvement in metastasis-related pain or symptoms of catecholamine excess [129]. A total of 67% of the procedures had no complications, and 14%, 14%, 2%, and 2% of the procedures had Clavien–Dindo Grade I, II, IV, and V complications, respectively [129].

The complications and risks of adrenal ablation include hemorrhage, infection, and hypertensive crisis [130]. Thermal ablation modalities can lead to injury to surrounding organs like the kidneys, pancreas, and lungs. Hormonal activation, leading to stroke or cardiac syndromes from catecholamine release, and tumor seeding of the ablation probe tract are other risks of ablation [124,130].

8. Thyroid and Parathyroid Tumors

While surgery is the main treatment option for patients with thyroid tumors, a growing number of studies have reported the safety and effectiveness of thermal ablations for thyroid tumors [131–140]. Several meta-analyses have also shown that thermal ablations are effective and safe alternatives [141–144] for primary and secondary hyperparathyroidism, primarily caused by parathyroid adenomas. Table 4 summarizes comparative studies on the various ablation modalities used, showing that RFA typically leads to superior volume reduction rates (VRR) for thyroid nodules when compared to other ablation modalities like MWA and laser ablation (LA). Comparative results of ablation modalities for parathyroid tumors are limited. Overall, ablation of thyroid and parathyroid tumors is becoming a more well-accepted alternative to surgery due to its minimal invasiveness and shorter recovery time [135,145]. Figure 13 discusses a representative case of a thyroid nodule ablation.
Table 4. Comparison of ablation modalities for thyroid and parathyroid tumors.

| Authors          | Study Type         | Inclusion Years | Sample Size | Comparison                      | Cancer                        | Findings                                                                 |
|------------------|--------------------|-----------------|-------------|---------------------------------|-------------------------------|--------------------------------------------------------------------------|
| Guo et al. [146] | Meta-analysis      | 2016–2019       | 1768 patients | RFA vs. MWA                     | Benign thyroid nodules        | Similar pooled 3- and 6-month volume reduction rate (VRR), symptom improvement, cosmetic scores, and complications. RFA showed superior 12-month VRR. |
| He et al. [147]  | Meta-analysis      | 1998–2015       | 873 patients | RFA vs. laser ablation (LA) vs. ethanol ablation (EA) | Benign thyroid nodules       | RFA had the highest VRR. No significant difference in complication rate. RFA is most efficacious for solid or mostly solid nodules, EA for cyst or mostly cyst nodules. |
| Zheng et al. [148]| Meta-analysis      | 2012–2018       | 1461 patients | Cooled MWA vs. uncooled MWA      | Benign thyroid nodules        | Similar pooled 3-month VRR and pooled proportion of major complications. Uncooled MWA had higher overall and minor complications with more pain and skin burns. |
| Ha et al. [149]  | Meta-analysis      | 2000–2013       | 184 patients | RFA vs. LA                      | Benign thyroid nodules        | RFA was superior to laser ablation in reducing volume with fewer treatment sessions. No major complications with either. |
| Choi and Jung [150]| Meta-analysis    | 2014–2019       | 715 patients | RFA vs. LA vs. MWA              | Primary papillary thyroid microcarcinoma (PTMC) | RFA had the highest mean VVR, followed by MWA and LA. Comparable safety profiles. |
| Suh et al. [151] | Meta-analysis      | 2008–2015       | 270 patients | RFA vs. EA                      | Locally recurrent thyroid cancer | RFA had a higher pooled VRR and pooled proportion of complete disappearance than EA. No significant difference in complication or recurrence rates. |
| Tong et al. [152]| Meta-analysis      | 2005–2017       | 1187 patients | RFA vs. MWA vs. LA              | PTMC                          | No significant difference in VVR, proportion of complete disappearance and recurrence, and in major complications rate. |
| Cho et al. [153] | Meta-analysis      | 1999–2018       | 1208 patients | RFA vs. LA                      | Benign thyroid nodules        | RFA had superior VRRs with less regrowth and delayed surgery. Comparable complication rates. |
| Trimboli et al. [135]| Meta-analysis | 2002–2019       | 3195 nodules  | RFA vs. LA                      | Benign non-functioning solid thyroid nodules | While both were effective in reducing volumes (maintained up to 2–3 years), RFA had superior VRRs. |
| Yang, Hsu, and Liou [154]| Meta-analysis | 1994–2020       | 1514 patients | EA vs. RFA vs. polidocanol sclerotherapy vs. simple aspiration | Benign thyroid cystic nodules | No significant difference in VRR and therapeutic success rate between EA and RFA. EA had a higher pooled VRR than other modalities. |
| Wei et al. [155] | Multicenter retrospective cohort | 2015–2020 | 119 | RFA vs. MWA | Primary hyperparathyroidism | No significant difference in cure rates at 6 months and overall complication rates. |

Abbreviations: LTR, local tumor recurrence; OS, overall survival; PFS, progression-free survival; NSD, no significant difference.
While ablation is generally safe for thyroid and parathyroid tumors, there are several risks and complications that may arise. The typical ones include hoarseness, hematomas, hypothyroidism, nerve injuries (especially to the laryngeal nerve), nodule rupture, skin burns, and hypocalcemia [156,157].

Figure 13. Thyroid nodule radiofrequency ablation. (A–C) Pre-ablation ultrasound images of solid nodule measuring 6.9 × 4.5 × 5.1 cm (white arrows). (D) Intraprocedure imaging shows trans-isthmic approach. (E,F) Post-ablation images show heterogeneous ablation changes throughout the nodule, and no internal vascularity. (G,H) One-month follow-up images show the nodule involuting and now measuring 5 × 3.1 × 2.8 cm.

9. Prostate Tumors

The recent increase in screening measures has led to the detection of prostate cancers at earlier stages, calling into question the current standard treatments of radical prostatectomy, high dose prostate brachytherapy, and external beam radiation therapy that target the whole-gland prostate and reduce quality of life [158,159]. New treatments have been developed that aim to achieve both tumor control and functional preservation by partial ablation of the prostate while sparing the structures crucial for genitourinary function [158].

The use of laser ablation for prostate tumors is gaining traction as it allows for the precise delivery to ablate tumors via coagulative necrosis while sparing prostate parenchyma. Results from a phase I clinical trial in eight men with intermediate-risk prostate cancer showed successful ablation with MR-guided focal laser ablation [160]. No grade 3 or higher adverse events, changes in International Prostate Symptom Score, nor International Index of Erectile Function 5 occurred at 6 months [160]. Seven men had their prostate specific antigen (PSA) decrease, and follow-up magnetic-resonance–ultrasound fusion biopsy did not detect residual disease in the ablation zone in five men but did find cancer outside the treatment margin in six men [160]. These results indicate the potential need to increase treatment margins. Promising results were seen in 120 patients with low-to
intermediate-risk prostate cancer who were treated with focal laser ablation, showing no changes in sexual and urinary functional scores, a decrease in PSA, and low morbidity [161]. A positive biopsy for clinically significant prostate cancer post-ablation was seen in 18 (15%) patients [161]. Figure 14 discusses the case of a patient with a prostate tumor treated with laser ablation.

![Figure 14. Laser ablation of prostate tumor. (A,B) Axial T2WI (A) and ADC (B) MR images show a right transition zone prostate lesion (white arrow) in a 66-year-old male with rising PSA and MR Bx positive for a Gleason score of $3 + 3 = 6$ cancer. MR-compatible 18G biopsy gun deployed into the target during in-bore MR biopsy (C). (D) Subsequent MR-guided focal laser ablation was performed, with post-ablation contrast-enhanced T1WI showing complete necrosis of the target tumor.](image)

HIFU is the most well-studied ablative modality used for prostate tumors and has shown to be effective for posterior lesions [158,162]. A prospective clinical trial reported that hemiablation HIFU therapy had promising functional and oncological outcomes in patients with localized, unilateral prostate cancer [163]. IRE is another focal therapy modality that has been gaining recent attention in men with prostate cancer. A recent meta-analysis demonstrated that IRE preserves urinary and erectile function at relatively high rates while also being safe with good oncologic outcomes. Figure 15 discusses the case of a patient with a prostate tumor treated with IRE. Other ablation techniques for prostate tumors include cryoablation, vascular-targeted photodynamic therapy (VP), RFA, MWA, and brachytherapy, but further comparative studies are needed.

While studies have shown the promise of ablation for prostate tumors, one of the present challenges in its adoption is adequate patient selection and precise disease localization [164,165]. The widespread adoption of multi-parametric MRI (mpMRI) has recently improved the detection of clinically significant prostate cancer, as evidenced by the PROMIS and PRECISION trials [166,167]. The mpMRI guidance has expanded the use of ablative modalities in prostate tumors, especially with transrectal ultrasound (TRUS)-MRI fusion for lesion targeting [165].
Figure 15. Irreversible electroporation of left prostate adenocarcinoma. A 64-year-old male with elevated PSA for which he underwent biopsy that showed adenocarcinoma in the left base of the prostate (white arrow) with Gleason score 7 and 8. (A–F) Contrast MR image of the prostate demonstrated a mass in the left peripheral zone. (G) He underwent IRE for the left side of his prostate. (H–M) Follow-up MR images show no residual tumor after 12 months. Abbreviations: ADC, apparent diffusion coefficient color-coded perfusion maps; DWI, diffusion-weighted imaging; DCE, color-coded dynamic contrast enhancement perfusion maps including K-Kep-CLR, K-trans, and Prim-FA.
While generally safe, there are several risks of ablation of the prostate. Most complications typically occur within the first month of ablation and include hematuria, urinary tract infection, pain and discomfort, erectile dysfunction, dysuria, and urethral sloughing [168]. Recto-urethral fistula is a potential complication but a rare one and most often occurs when focal therapy is administered in a salvage setting and when the tumor is in the posterior portion of the prostate with extracapsular extension [168].

10. Primary and Metastatic Lung Tumors

Lung cancer is the leading cause of cancer death for both men and women worldwide [169]. While radical resection is the treatment of choice for patients with lung cancer, only about 20–30% of patients are operable [170]. Image-guided thermal ablation is one of the many non-surgical treatments that patients with unresectable lung cancer can have. The most widely used ablative techniques for lung cancer are RFA, MWA, and cryoablation [171]. Table 5 summarizes most comparative studies that have been carried out presently, showing that RFA and MWA are comparable regarding outcomes and safety, while cryoablation still needs to be studied further. Figure 16 discusses the case of a patient with right lower lobe lung lesion treated with cryoablation. Very few studies address primary lung cancer alone and combine primary tumors with pulmonary metastases.

| Authors | Study Type | Inclusion Years | Sample Size | Comparison | Cancer | Findings |
|---------|------------|-----------------|-------------|------------|--------|----------|
| Chi et al. [172] | Retrospective Cohort + Meta-analysis | 2003–2018 | 590 | RFA vs. MWA | Primary and metastatic lung tumors | No significant difference in complication rates, complete ablation rates, median progression-free and overall survival |
| Macchi et al. [173] | RCT | N/A | 52 | RFA vs. MWA | Stage IV lung cancer | No significant difference in survival. MWA had significantly lower pain levels and a greater tumor size reduction |
| Bi et al. [174] | Meta-analysis | 2004–2012 | 3095 | RFA vs. SBRT | Stage I NSCLC | SBRT had significantly higher local tumor control rates. Comparable overall survival |
| Jiang et al. [175] | Meta-analysis | 2004–2017 | 1840 | RFA vs. MWA vs. cryoablation | Primary and metastatic tumors | RFA and MWA are more effective at controlling local progression rate than cryoablation. Comparable safety profiles across all three. |
| Yuan et al. [176] | Meta-analysis | 2010–2017 | 3432 | RFA vs. MWA | Primary and metastatic tumors | 1–5 year overall survival higher in RFA. No significant difference in median local tumor progression free survival, complete ablation rates, and adverse events. RFA had higher median survival in metastatic tumors. |

Abbreviations: LTR, local tumor recurrence; OS, overall survival; PFS, progression-free survival; NSD, no significant difference.

While ablation is generally safe in patients with lung cancer with a mortality rate <1%, it has the potential to lead to multiple complications, including pneumothorax, pleural effusion, and parenchymal hemorrhage [177]. Potentially fatal complications typically include major hemorrhage, pneumothorax that becomes intractable due to bronchopleural fistula, pulmonary artery pseudoaneurysm, formation of systemic air embolism, and pneumonitis [177]. A single center’s experience with 1000 RFAs in 420 patients found four deaths related to RFA, of which three patients died of interstitial pneumonia and one of hemothorax [178]. The major complication rate was 9.8%, and frequent complications
include aseptic pleuritis (2.3%), pneumonia (1.8%), lung abscess (1.6%), bleeding that required blood transfusion (1.6%), pneumothorax that required pleural sclerosis (1.6%), bronchopleural fistula (0.4%), brachial nerve injury (0.3%), tumor seeding (0.1%), and diaphragm injury (0.1%) [178]. A single center’s experience with 204 MWAs in 184 patients found a major complication rate of 20.6%, in which 15.7% of cases resulted in pneumothorax, 2.9% of cases resulted in pleural effusions requiring chest tube placements, and 2.9% of cases resulted in pneumonia [179]. With regard to cryoablation, the most common complications include pneumothorax, hemoptysis, pleural effusion, injury to the phrenic nerve, and implantation of the tumor [180].

11. Primary and Metastatic Bone Tumors

Bone is a common site of metastasis and lesions here are often painful and can lead to many complications like fractures, hypercalcemia, and spinal cord compression [181–183]. While surgical resection and bone curettage are the primary treatment for bone tumors, not all tumors can be accessed surgically and the can often impact the quality of life by affecting

Figure 16. Cryoablation of right lower lobe lung metastatic lesion suspected for colorectal cancer metastasis. (A,B) CT images of the chest show the 1.2 cm nodule (white arrow) in the right lower lobe of the lung. (C) Under CT image-guidance, two Endocare PCS-17R cryoablation probes were advanced via a posterior approach, which bracketed the tumor to optimize the ablation coverage of the lesion. (D) Under CT image-guidance, a 19-gauge needle was advanced down to the lesion. An image was obtained and placed into the medical record. Samples were obtained for evaluation. Cryoablation was performed with three freeze cycles that lasted three, seven, and ten minutes, respectively, interposed with three minutes passive thaw cycles. (E) 6 and (F) 12-month follow up images show shrinking scar.
ambulation and causing pain [184]. Recent attention has been placed on minimally invasive
techniques that can improve both quality of life and local tumor control in patients with
bone tumors [184,185]. These techniques include percutaneous thermal ablation like RFA,
MWA, and cryoablation that are becoming well-established as safe and effective treatment
options for primary and metastatic tumors [182,186].

A 2019 meta-analysis involving RFA, MWA, cryoablation, and magnetic-resonance-
guided focused ultrasound (MRgFUS) found that all techniques resulted in pain relief
after 1 and 3 months, in up to 91% and 95% of patients, respectively, though MRgFUS was
found to have a noteworthy complication rate while the others were relatively safe [186].
While more comparative studies are needed, several systematic reviews, clinical trials, and
cohort studies have shown the safety and effectiveness of RFA, MWA, and cryoablation for
primary and metastatic bone tumors [184,187–195].

Each of the primary ablation modalities has specific clinical indications and established
clinical applications. With regards to RFA, it can be used to treat benign tumors and has been
advocated as a first-line treatment for spinal osteoid osteomas (OOs) and osteoblastomas
(OBs) as it is associated with improved pain scores and quality of life [196]. RFA is also
effective for managing painful primary and metastatic bone tumors, especially those ≤2 cm
in size, as well as lytic tumors with neoangiogenesis and mechanical instability [196].
Figure 17 discusses the case of a patient with a well-corticated osteoid osteoma in the
posteromedial tibial metaphysis treated with RFA.

Figure 17. Radiofrequency ablation of osteoid osteoma. (A) A well-corticated osteoid osteoma
with hypodense nidus (white arrow) in the posteromedial tibial metaphysis, (B) treated with RFA.
(C–F) 5-month follow-up MR images show treated osteoid osteoma without residual lesion.

Cryoablation is useful for bone tumors in that it can produce very large ablation zones
with less pain in contrast to other modalities. It is also favored in sclerotic metastases
compared to RFA due to the insulating effects of cortical bone. However, cryoablation is
limited in that the ice ball size cannot be visualized in dense bone, and it can be associated
with technical difficulty for tumors close to vital structures like the spinal cord or nerves.
It is favored in sclerotic metastases when compared to RFA due to the insulating effects
of cortical bone. Furthermore, cryoablation has fewer neural complications as it does not require electrical changes [196]. MWA has faster coagulation times, deeper penetration, and experiences reduced osseous impedance when compared to other ablative modalities, making it useful for deep and large lesions with less heat sink and charring buildup effects [196]. However, manufacturer guidelines are mainly calibrated for soft tissue tumors; hence, parameters for bone tumors need further optimization [197].

Interstitial laser ablation is also used in bone tumors and offers great precision with minimal effects to adjacent tissues and reduces costs for chemoprotection with extraspinal bone procedures [196]. This modality also preserves the overlying skin, providing a favorable cosmetic outcome.

MRg-HIFU is a noninvasive modality that has been used for OO and OB as well as bone metastasis, multiple myeloma, plasmacytoma, and other diseases [196]. It is particularly useful for flat bones with thin cortices (e.g., the iliac bone and scapula) with a low-volume disease load due to the insulating properties of cortical bone [196]. They are best suited for lesions between 1 cm and 12 cm as they cannot be too close for risk of skin burns and cannot be too deep given the poor penetrability of US [196].

Ablation for bone tumors is generally safe. In a retrospective study of 169 patients undergoing RFA for 217 tumors, the major complication rate was 2.3% (five patients) with four patients having secondary fractures [198]. The minor complication rate was 27.7% (60 patients) with the most frequent complication being immediate postoperative pain [198]. Other risks to ablating bone tumors include cortical loss and cement leakage [199]. This leakage is particularly more vulnerable when osteoplasty is done with cryoablation as the cooler temperature delays cement polymerization [199]. In contrast, thermal ablation modalities can accelerate cement polymerization and prevent further injection to strengthen the bone [199]. Other complications include inadvertent nerve and osteochondral injury near bone [199].

12. Primary and Metastatic Soft Tissue Tumors

Like bone tumors, soft tissue tumors can lead to chronic, severe pain and many complications, such as ulceration and mass effect [200]. While many soft tissue tumors are radiosensitive, a lot of them are not suited for radiation or surgery due to their location and adjacent structure, in which case, ablation remains an option. Percutaneous ablation can also prevent ulceration in certain soft tissue tumors of the skin or superficial locations [200].

The CRYODESMO-01 prospective, open-label non-randomized, non-comparative, multicenter trial found that cryoablation significantly improved functional status, reduced pain, and led to long-term disease control in non-abdominopelvic progressing desmoid tumors [201]. Cryoablation, as well as laser ablation, has also been shown to be effective as second-line treatments for certain symptomatic vascular anomalies [202]. Figure 18 demonstrates a case of a patient with right breast sarcoma treated with CT-guided cryoablation.

RFA has been shown to be effective for desmoid tumors, myeloma, soft tissue metastasis, and plasmacytomas [196,203]. Multiple studies have found RFA to be associated with high local tumor control rates with favorable overall survivals and minimal adverse events [204–207]. Currently, RFA is the most widely used technique for metastatic sarcoma [208].

Like in bone tumors, HIFU is also particularly useful in treating soft tissue tumors. It has been utilized for metastasis, multiple myeloma, plasmacytoma, and many other focal myeloproliferative disorders [196]. A multicenter retrospective analysis found that MRgFUS significantly reduced tumor volumes and pain in fifteen patients with extra-abdominal desmoid fibromatosis [209].

Complications of soft tissue tumors are similar to those of bone tumors, and most are due to the tumor’s location. If superficially located, these soft tissue tumors can lead to skin injury when ablated. Furthermore, there can be iatrogenic thermal damage to surrounding structures like nervous tissue, adjacent bowel, or other viscera [200].
Figure 18. Right breast sarcoma treated with CT-guided cryoablation. (A) Axial gadolinium-enhanced T1-weighted, fat-suppressed MR image shows a lobulated right breast sarcoma mass (white arrow). (B) Axial pre-cryoablation, non-enhanced CT image shows target lobulated right breast lesion (white arrow). (C) Axial non-enhanced CT image during cryoablation shows two cryoprobes (white arrows) traversing the target lesion (white arrowheads). The lesion is less visible having become nearly iso-dense to fat due to freezing. (D) Axial non-enhanced CT image at the conclusion of cryoablation shows the two cryoprobe-ghost trajectories (white arrows) after the probes were removed (white arrowheads). (E) Axial gadolinium-enhanced T1-weighted, fat-suppressed MR image 2-years after cryoablation, shows a shrinking, non-enhancing, necrotic lesion surrounded by a thin rim of fibrous tissue (arrowheads).

13. Conclusions

Image-guided percutaneous ablation is becoming a well-established alternative to surgery in many different cancers as there is growing evidence of its effectiveness and safety profile in ablating both primary and metastatic tumors in various organs. Ablation allows for shorter recovery, less bleeding, and fewer risks than conventional treatment, and is transforming the treatment options available for patients. As this minimally invasive practice is becoming more widely adopted with frequent advancements in both technique and available ablation modalities, more efforts are needed to establish and update existing protocols to include ablation in the treatment of oncologic patients.

Author Contributions: All authors have contributed to their associated sections. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: T.G. serves on the editorial board of RadioGraphics and Pediatrics Oncall. N.N. is consultant to Embolix, RenovoRx, and CAPS Medical.
References

1. Ahmed, M.; Solbiati, L.; Brace, C.L.; Breen, D.J.; Callstrom, M.R.; Charboneau, J.W.; Chen, M.H.; Choi, B.I.; de Baère, T.; Dodd, G.D.; III; et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria—a 10-year update. *Radiology* **2014**, *273*, 241–260. [CrossRef] [PubMed]

2. Ridouani, F.; Srimathveeravalli, G. Percutaneous image-guided ablation: From techniques to treatments. *Presse Med.* **2019**, *48*, e219–e231. [CrossRef] [PubMed]

3. Smith, K.A.; Kim, H.S. Interventional radiology and image-guided medicine: Interventional oncology. *Semin Oncol.* **2011**, *38*, 151–162. [CrossRef] [PubMed]

4. Auloge, P.; Cazzato, R.L.; Koch, G.; Caudrelier, J.; De Marini, P.; Garnon, J.; Gangi, A. Percutaneous tumor ablation. *Presse Med.* **2019**, *48*, 1146–1155. [CrossRef] [PubMed]

5. Nadeem, S.; Zhang, P.; Rimner, A.; Sonke, J.J.; Deasy, J.O.; Tannenbaum, A. IDeform: Longitudinal deformation analysis for adaptive radiotherapy of lung cancer. *Med. Phys.* **2020**, *47*, 132–141. [CrossRef] [PubMed]

6. Nakao, M.; Nakamura, M.; Mizowaki, T.; Matsuda, T. Statistical deformation reconstruction using multi-organ shape features for pancreatic cancer localization. *Med. Image Anal.* **2021**, *67*, 101829. [CrossRef]

7. Xu, X.; Carrera, E.; Augello, R.; Daneshkhah, E.; Yang, H. Benchmarks for higher-order modes evaluation in the free vibration response of open thin-walled beams due to the cross-sectional deformations. *Thin-Walled Struct.* **2021**, *166*, 107965. [CrossRef]

8. Goldberg, S.N.; Gazelle, G.S.; Mueller, P.R. Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance. *AJR Am. J. Roentgenol.* **2000**, *174*, 324–331. [CrossRef]

9. Mauri, G.; Nicosia, L.; Varano, G.M.; Bonomo, G.; Della Vigna, P.; Monfardini, L.; Orsi, F. Tips and tricks for a safe and effective image-guided percutaneous renal tumor ablation. *Insights Imaging* **2017**, *8*, 357–363. [CrossRef]

10. Carriero, S.; Della Pepa, G.; Monfardini, L.; Vitale, R.; Rossi, D.; Masperi, A.; Mauri, G. Role of Fusion Imaging in Image-Guided Thermal Ablations. *Diagnoses* **2021**, *11*, 549. [CrossRef]

11. Zhou, Y.; Yang, Y.; Zhou, B.; Wang, Z.; Zhu, R.; Chen, X.; Ouyang, J.; Li, Q.; Zhou, J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. *J. Hepatocell. Carcinoma* **2021**, *8*, 625–644. [CrossRef] [PubMed]

12. Citone, M.; Fanelli, F.; Falcone, G.; Mondaini, F.; Cozzi, D.; Miele, V. A closer look to the new frontier of artificial intelligence in the percutaneous treatment of primary lesions of the liver. *Med. Oncol.* **2020**, *37*, 55. [CrossRef] [PubMed]

13. Kamal, A.; Elmoety, A.A.A.; Rostom, Y.A.M.; Shater, M.S.; Lashen, S.A. Percutaneous radiofrequency versus microwave ablation for management of hepatocellular carcinoma: A randomized controlled trial. *J. Gastrointest. Oncol.* **2019**, *10*, 562–571. [CrossRef] [PubMed]

14. Malone, C.D.; Fetzer, D.T.; Monsky, W.L.; Itani, M.; Mellnick, V.M.; Velez, P.A.; Middleton, W.D.; Averkiou, M.A.; Ramaswamy, R.S. Contrast-enhanced US for the Interventional Radiologist: Current and Emerging Applications. *Radiographics* **2020**, *40*, 562–588. [CrossRef]

15. Claudon, M.; Dietrich, C.F.; Choi, B.I.; Cosgrove, D.O.; Kudo, M.; Nolsee, C.P.; Piccoli, F.; Wilson, S.R.; Barr, R.G.; Chammas, M.C.; et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver—Update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. *Ultraschall. Med.* **2013**, *34*, 11–29. [CrossRef]

16. Huang, Q.; Zeng, Q.; Long, Y.; Tan, L.; Zheng, R.; Xu, E.; Li, K. Fusion imaging techniques and contrast-enhanced ultrasound for thermal ablation of hepatocellular carcinoma—a prospective randomized controlled trial. *Int. J. Hyperth.* **2019**, *36*, 1207–1215. [CrossRef]

17. Sánchez, Y.; Anvari, A.; Samir, A.E.; Arellano, R.S.; Prabhakar, A.M.; Upptom, R.N. Navigational Guidance and Ablation Planning Tools for Interventional Radiology. *Curr. Probl. Diagn. Radiol.* **2017**, *46*, 225–233. [CrossRef]

18. Meziane, M. Computed Tomography Fluoroscopy. *J. Bronchol. Interv. Pulmonol.* **2005**, *12*, 69–70. [CrossRef]

19. Maybodey, M. An overview of image-guided percutaneous ablation of renal tumors. *Semin. Inter. Radiol.* **2010**, *27*, 261–267. [CrossRef]

20. Lakhoo, J.; Adams, R.; Dave, A.; Luo, L.; Vargo, C.J.; Isaacson, A.J.; Sher, A.; Fischman, A.; Yee, D.C.; Ryan, S.; et al. Radioopaque beads loaded with doxorubicin in the treatment of patients with hepatocellular carcinoma: A retrospective, multi-center study. *Cancer Treat. Res. Commun.* **2020**, *25*, 100208. [CrossRef]

21. Dreher, M.R.; Sharma, K.V.; Woods, D.L.; Reddy, G.; Tang, Y.; Pritchard, W.F.; Chiesa, O.A.; Karanian, J.W.; Esperza, J.A.; Donahue, D.; et al. Radioactive drug-eluting beads for transcatheter embolotherapy: Experimental study of drug penetration and coverage in swine. *J. Vasc. Inter. Radiol.* **2012**, *23*, 257–264.e254. [CrossRef] [PubMed]

22. Fartoux, L.; Arrive, I.; Andreani, T.; Serfaty, L.; Chazouilleres, O.; Tubiana, J.M.; Poupon, R.; Rosmorduc, O. Treatment of small hepatocellular carcinoma with acetic acid percutaneous injection. *Gastroenterol. Clin. Biol.* **2005**, *29*, 1213–1219. [CrossRef]

23. Livraghi, T.; Giorgio, A.; Marin, G.; Salmi, A.; de Sio, I.; Bolondi, L.; Pompili, M.; Brunello, F.; Lazzeroni, S.; Torzilli, G.; et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. *Radiology* **1995**, *197*, 101–108. [CrossRef] [PubMed]

24. Alzubaidi, S.J.; Liou, H.; Saini, G.; Segaran, N.; Scott Kriegshauser, J.; Naidu, S.G.; Patel, I.J.; Oklu, R. Percutaneous Image-Guided Ablation of Lung Tumors. *J. Clin. Med.* **2021**, *10*, 5783. [CrossRef]
52. Poulou, L.S.; Botsa, E.; Thanou, I.; Ziakas, P.D.; Thanos, L. Percutaneous microwave ablation vs. radiofrequency ablation in the treatment of hepatocellular carcinoma. *World J. Hepatol.* 2015, 7, 1054–1063. [CrossRef] [PubMed]

53. Abdelaziz, A.; Elbaz, T.; Shousha, H.I.; Mahmoud, S.; Ibrahim, M.; Abdelmaksoud, A.; Nabeel, M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: An Egyptian multidisciplinary clinic experience. *Surg. Endosc.* 2014, 28, 3429–3434. [CrossRef] [PubMed]

54. Yu, J.; Yu, X.L.; Han, Z.Y.; Cheng, Z.G.; Liu, F.Y.; Zhai, H.Y.; Mu, M.J.; Liu, Y.M.; Liang, P. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase III randomised controlled trial. *Gut* 2017, 66, 1172–1173. [CrossRef]

55. Vietti Violì, N.; Duran, R.; Guiu, B.; Cercueil, J.P.; Aubé, C.; Digklia, A.; Pache, J.; Deltenre, P.; Knebel, J.F.; Denys, A. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: A randomised controlled phase 2 trial. *Lancet Gastroenterol. Hepatol.* 2018, 3, 317–325. [CrossRef]

56. Shibata, T.; Iimuro, Y.; Yamamoto, Y.; Maetani, Y.; Ametani, F.; Itoh, K.; Konishi, J. Small hepatocellular carcinoma: Comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. *Radiology* 2002, 223, 331–337. [CrossRef]

57. Glassberg, M.B.; Ghosh, S.; Clymer, J.W.; Wright, G.W.J.; Ferko, N.; Amaral, J.F. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and meta-analysis. *World J. Surg. Oncol.* 2019, 17, 98. [CrossRef]

58. McWilliams, J.P.; Yamamoto, S.; Raman, S.S.; Loh, C.T.; Lee, E.W.; Liu, D.M.; Kee, S.T. Percutaneous ablation of hepatocellular carcinoma: A Systematic Review and Literature-Based Analysis. *Arch. Surg.* 2000, 135, 657–662; discussion 662–654. [CrossRef] [PubMed]

59. Chung, T.T.; Chu, F.S.; Jenkins, C.R.; Tsang, S.H.; Dai, W.C.; Chan, A.C.; Chan, S.C.; Yau, T.C.; Lo, E.Y.J.; et al. Prospective double-blind randomized controlled trial of Microwave versus Radiofrequency Ablation for hepatocellular carcinoma (MrFA trial). *HPB* 2020, 22, 1121–1127. [CrossRef] [PubMed]

60. Wu, S.; Hou, J.; Ding, Y.; Yu, F.; Hu, Y.; Jiang, Q.; Mao, P.; Yang, Y. Cryoablation Versus Radiofrequency Ablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study. *Eur. J. Surg. Oncol.* 2019, 45, S204–S213. [CrossRef] [PubMed]

61. Cheung, S.Y.S.; Chu, C.C.M.; Fong, A.K.W.; Wenniger, C.; Ramaswamy, R.; Tao, Y.U.; Akinwande, O. Radiofrequency Ablation vs. Cryoablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study. *Anticancer Res.* 2018, 38, 6381–6386. [CrossRef] [PubMed]

62. Wang, K. Percutaneous microwave ablation versus radiofrequency ablation for early stage hepatocellular carcinoma: A PRISMA-compliant systematic review and meta-analysis. *Medicine* 2020, 99, e22703. [CrossRef] [PubMed]

63. Xu, J.; Noda, C.; Erickson, A.; Mokkarala, M.; Charalel, R.; Ramaswamy, R.; Tao, Y.U.; Akinwande, O. Radiofrequency Ablation Versus Cryoablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study. *Eur. J. Surg. Oncol.* 2019, 45, S204–S213. [CrossRef] [PubMed]

64. Frühling, P.; Nilsson, A.; Duraj, F.; Haglund, U.; Laubenberg, J.; Zubler, I.; Blüm, H.E.; et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. *Radiology* 2003, 228, 235–240. [CrossRef]

65. Li, K.; Tan, W.; Zhang, W.; Wang, X.; Hu, K.; Li, X.; Kar, D.; Chen, Y.; et al. Efficacy and survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. *HPB* 2017, 19, 751–757. [CrossRef] [PubMed]

66. Chong, C.C.N.; Lee, K.F.; Cheung, S.Y.S.; Chu, C.C.M.; Fong, A.K.W.; Wenniger, C.; Ramaswamy, R.; Tao, Y.U.; Akinwande, O. Radiofrequency Ablation Versus Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma in Patients with Chronic Liver Disease: A Randomised Controlled Trial. *Eur. J. Radiol.* 2017, 89, 235–240. [CrossRef] [PubMed]

67. de Vries, J.J.J.; van Lienden, K.P.; et al. Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-II): A Phase II, Two-Center, Single-Arm Clinical Trial. *Radiology* 2021, 299, 470–480. [PubMed]

68. Frühling, P.; Nilsson, A.; Duraj, F.; Haglund, U.; Norén, A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results. *Eur J. Surg. Oncol.* 2017, 43, 751–757. [CrossRef]

69. Tian, G.; Zhao, Q.; Chen, F.; Jiang, T.; Wang, W. Ablation of hepatic malignant tumors with irreversible electroporation: A systematic review and meta-analysis of outcomes. *Oncoarget* 2017, 8, 5853–5860. [CrossRef]

70. Gupta, P.; Maralakunte, M.; Sagar, S.; Kumar, M.P.; Bhujade, H.; Chaluvasheetty, S.B.; Kalra, N. Efficacy and safety of irreversible electroporation for malignant liver tumors: A systematic review and meta-analysis. *Eur. Radiol.* 2021, 31, 6511–6521. [CrossRef] [PubMed]

71. Yu, M.; Li, S. Irreversible electroporation for liver cancer ablation: A meta analysis. *Eur. J. Surg. Oncol.* 2021, in press. [CrossRef]

72. Lyu, T.; Wang, X.; Su, Z.; Shangguan, J.; Sun, C.; Figini, M.; Wang, J.; Yaghmai, V.; Larson, A.; Zhang, Z. Irreversible electroporation in primary and metastatic hepatic malignancies: A review. *Medicine* 2017, 96, e6386. [CrossRef] [PubMed]

73. Cheung, T.T.; Fan, S.T.; Chu, F.S.; Jenkins, C.R.; Chok, K.S.; Tsang, S.H.; Dai, W.C.; Chan, A.C.; Chan, S.C.; Yau, T.C.; et al. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. *HPB* 2013, 15, 567–573. [CrossRef] [PubMed]

74. Cheung, T.T.; Chu, F.S.; Jenkins, C.R.; Tsang, D.S.; Chok, K.S.; Chan, A.C.; Yau, T.C.; Chan, S.C.; Poon, R.T.; Lo, C.M.; et al. Tolerance of high-intensity focused ultrasound ablation in patients with hepatocellular carcinoma. *World J. Surg.* 2012, 36, 2420–2427. [CrossRef] [PubMed]

75. Xu, G.; Luo, G.; He, L.; Li, J.; Shan, H.; Zhang, R.; Li, Y.; Gao, X.; Lin, S.; Wang, G. Follow-up of high-intensity focused ultrasound treatment for patients with hepatocellular carcinoma. *Ultrasound Med. Biol.* 2011, 37, 1993–1999. [CrossRef] [PubMed]
76. Fukuda, H.; Ito, R.; Ohito, M.; Sakamoto, A.; Karasawa, E.; Yamaguchi, T.; Shinozuka, N.; Zhu, H.; Wang, Z.B. Treatment of small hepatocellular carcinomas with US-guided high-intensity focused ultrasound. *Ultrasound Med. Biol.* 2011, 37, 1222–1229. [CrossRef]

77. Ng, K.K.; Poon, R.T.; Chan, S.C.; Chok, K.S.; Cheung, T.T.; Tung, H.; Chu, F.; Tso, W.K.; Yu, W.C.; Lo, C.M.; et al. High-intensity focused ultrasound for hepatocellular carcinoma: A single-center experience. *Ann. Surg.* 2011, 253, 981–987. [CrossRef]

78. Ji, Y.; Zhu, J.; Zhu, L.; Zhu, Y.; Zhao, H. High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center with 275 Cases. *Front. Oncol.* 2020, 10, 519164. [CrossRef]

79. Chan, A.C.; Cheung, T.T.; Fan, S.T.; Chok, K.S.; Chan, S.C.; Poon, R.T.; Lo, C.M. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. *Ann. Surg.* 2013, 257, 686–692. [CrossRef]

80. Yu, S.J.; Yoon, J.H.; Lee, J.M.; Lee, J.Y.; Kim, S.H.; Cho, Y.Y.; Yoo, J.J.; Lee, M.; Lee, D.H.; Cho, Y.; et al. Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm: A matched case-control comparative analysis. *Medicine* 2016, 95, e4551. [CrossRef]

81. Yang, B.; Zan, R.Y.; Wang, S.Y.; Li, X.L.; Wei, M.L.; Guo, W.H.; You, X.; Li, J.; Liao, Z.Y. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: A meta-analysis of randomized controlled trials. *World J. Surg.* 2015, 13, 96. [CrossRef]

82. Chen, L.; Ren, Y.; Sun, T.; Cao, Y.; Yan, L.; Zhang, W.; Ouyang, T.; Zheng, C. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study. *Cancer Med.* 2020, 10, 3715–3725. [CrossRef]

83. Glassberg, M.B.; Ghosh, S.; Clymer, J.W.; Qadeer, R.A.; Ferko, N.C.; Sadeghirad, B.; Wright, G.W.; Amaral, J.F. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: A systematic review and meta-analysis. *OncoTargets Ther.* 2019, 12, 6407–6438. [CrossRef] [PubMed]

84. Kim, K.R.; Thomas, S. Complications of image-guided thermal ablation of liver and kidney neoplasms. *Semin. Interv. Radiol.* 2014, 31, 138–148. [CrossRef]

85. Lahat, E.; Eshkenazy, R.; Zendel, A.; Zakai, B.B.; Maor, M.; Dreznik, Y.; Ariche, A. Complications after percutaneous ablation of liver tumors: A systematic review. *Hepatobiliary Surg. Nurst.* 2014, 3, 317–323. [CrossRef] [PubMed]

86. Zimmerman, A.; Grand, D.; Charpentier, K.P. Irreversible electroporation of hepatocellular carcinoma: Patient selection and perspectives. *J. Hepatobiliary Pancreat. Sci.* 2017, 4, 49–58. [CrossRef]

87. Alnaggar, M.; Qaid, A.M.; Chen, J.; Niu, L.; Xu, K. Irreversible electroporation of malignant liver tumors: Effect on laboratory values. *Oncol. Lett.* 2018, 16, 3881–3888. [CrossRef]

88. Tsang, S.H.; Ma, K.W.; She, W.H.; Chu, F.; Lau, V.; Lam, S.W.; Cheung, T.T.; Lo, C.M. High-intensity focused ultrasound ablation of liver tumors in difficult locations. *Int. J. Hyperth.* 2021, 38, 56–64. [CrossRef]

89. Herr, H.W. A history of partial nephrectomy for renal tumors. *J. Urol.* 2005, 173, 705–708. [CrossRef]

90. Pierorazio, P.M.; Johnson, M.H.; Patel, H.D.; Sozio, S.M.; Sharma, R.; Iyoha, E.; Bass, E.B.; Allaf, M.E. AHRQ Comparative Effectiveness Reviews. In *Management of Renal Masses and Localized Renal Cancer*; Agency for Healthcare Research and Quality: Rockville, MD, USA, 2016.

91. Ljungberg, B.; Cowan, N.C.; Hanbury, D.C.; Hora, M.; Kuczyk, M.A.; Merseburger, A.S.; Patard, J.J.; Mulders, P.F.; Sinescu, I.C. EAU guidelines on renal cell carcinoma: The 2010 update. *Eur. Urol.* 2010, 58, 398–406. [CrossRef]

92. Thompson, R.H.; Atwell, T.; Schmit, G.; Lohe, C.M.; Kurup, A.N.; Weisbrod, A.; Psutka, S.P.; Stewart, S.B.; Callstrom, M.R.; Cheville, J.C.; et al. Reply to Pascal Mouracade’s letter to the editor re: R. Houston Thompson, Tom Atwell, Grant Schmit; et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. *Eur. Urol.* 2015;67:252–9. *Eur. Urol.* 2015, 68, e84–e85. [CrossRef]

93. Gervais, D.A.; McGovern, F.J.; Wood, B.J.; Goldberg, S.N.; McDougal, W.S.; Mueller, P.R. Radio-frequency ablation of renal cell carcinoma: Early clinical experience. *Radiology* 2000, 217, 665–672. [CrossRef]

94. Jasinski, M.; Siekiera, J.; Chlosta, P.; Mikolajczak, W.; Drewa, T. Radiofrequency ablation of small renal masses as an alternative to nephron-sparing surgery: Preliminary results. *Wio tecr. Inne Tech. Maloznawcze* 2011, 6, 242–245. [CrossRef] [PubMed]

95. Frey, G.T.; Sellu, D.M.; Atwell, T.D. Image-Guided Renal Intervention. *Radiol. Clin. N. Am.* 2015, 53, 1005–1019. [CrossRef] [PubMed]

96. Cazalas, G.; Jambon, E.; Coussy, A.; Le Bras, Y.; Petitpierre, F.; Berhnard, J.C.; Grenier, N.; Marcelin, C. Local recurrence and other oncologic outcomes after percutaneous image-guided tumor ablations on stage T1b renal cell carcinoma: A systematic review and network meta-analysis. *Int. J. Hyperth.* 2021, 38, 1295–1303. [CrossRef] [PubMed]

97. National Comprehensive Cancer Network. Kidney Cancer (Version 4.2022). Available online: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (accessed on 1 January 2022).

98. Thompson, R.H.; Atwell, T.; Schmit, G.; Lohe, C.M.; Kurup, A.N.; Weisbrod, A.; Psutka, S.P.; Stewart, S.B.; Callstrom, M.R.; Cheville, J.C.; et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. *Eur. Urol.* 2015, 67, 252–259. [CrossRef]

99. Atwell, T.D.; Schmit, G.D.; Boorjian, S.A.; Mandrekas, J.; Kurup, A.N.; Weisbrod, A.; Chow, G.K.; Leibovich, B.C.; Callstrom, M.R.; Patterson, D.E.; et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: Comparative local control and complications after radiofrequency ablation and cryoablation. *AJR Am. J. Roentgenol.* 2013, 200, 461–466. [CrossRef]
Diagnostics 2022, 12, 1300

100. El Dib, R.; Touma, N.J.; Kapoor, A. Cryoablation vs. radiofrequency ablation for the treatment of renal cell carcinoma: A meta-analysis of case series studies. BJU Int. 2012, 110, 510–516. [CrossRef]

101. Atwell, T.D.; Carter, R.E.; Schmit, G.D.; Carr, C.M.; Boorjian, S.A.; Curry, T.B.; Thompson, R.H.; Kurup, A.N.; Weisbrod, A.J.; Chow, G.K.; et al. Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J. Vasc. Interv. Radiol. 2012, 23, 48–54. [CrossRef]

102. Andrews, J.R.; Atwell, T.; Schmit, G.; Lobse, C.M.; Kurup, A.N.; Weisbrod, A.; Callstrom, M.R.; Cheville, J.C.; Boorjian, S.A.; Leibovich, B.C.; et al. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur. Urol. 2019, 76, 244–251. [CrossRef]

103. Zhong, J.; Wah, T.M. Renal ablation: Current management strategies and controversies. Chin. Clin. Oncol. 2019, 8, 63. [CrossRef]

104. Psutka, S.P.; Feldman, A.S.; McDougal, W.S.; McGovern, F.J.; Mueller, P.; Gervais, D.A. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur. Urol. 2013, 63, 486–492. [CrossRef]

105. Atwell, T.D.; Vlaminck, J.J.; Boorjian, S.A.; Kurup, A.N.; Callstrom, M.R.; Weisbrod, A.J.; Lobse, C.M.; Hartman, W.R.; Stockland, A.H.; Leibovich, B.C.; et al. Percutaneous cryoablation of stage T1b renal cell carcinoma: Technique considerations, safety, and local tumor control. J. Vasc. Interv. Radiol. 2015, 26, 792–799. [CrossRef] [PubMed]

106. Schmit, G.D.; Atwell, T.D.; Callstrom, M.R.; Farrell, M.A.; Leibovich, B.C.; Patterson, D.E.; Chow, G.K.; Blute, M.L.; Charboneau, J.W. Percutaneous cryoablation of renal masses >or=3 cm: Efficacy and safety in treatment of 108 patients. J. Endourol. 2010, 24, 1255–1262. [CrossRef] [PubMed]

107. Zhou, W.; Arellano, R.S. Thermal Ablation of T1c Renal Cell Carcinoma: A Comparative Assessment of Technical Performance, Procedural Outcome, and Safety of Microwave Ablation, Radiofrequency Ablation, and Cryoablation. J. Vasc. Interv. Radiol. 2018, 29, 943–951. [CrossRef]

108. Martin, J.; Athreya, S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: Is there a difference in outcome? Diagn. Interv. Radiol. 2013, 19, 501–507. [CrossRef] [PubMed]

109. Zhou, W.; Herwald, S.E.; McCarthy, C.; Uppot, R.N.; Arellano, R.S. Radiofrequency Ablation, Cryoablation, and Microwave Ablation for T1a Renal Cell Carcinoma: A Comparative Evaluation of Therapeutic and Renal Function Outcomes. J. Vasc. Interv. Radiol. 2019, 30, 1035–1042. [CrossRef] [PubMed]

110. Kurup, A.N. Percutaneous ablation for small renal masses-complications. Semin. Interv. Radiol. 2014, 31, 42–49. [CrossRef]

111. Dong, X.; Li, X.; Yu, J.; Yu, M.A.; Yu, X.; Liang, F. Complications of ultrasound-guided percutaneous microwave ablation of renal cell carcinoma. OncoTargets Ther. 2016, 9, 5903–5909. [CrossRef]

112. Patel, I.J.; Rahim, S.; Davidson, J.C.; Hanks, S.E.; Tam, A.L.; Walker, T.G.; Wilkins, L.R.; Sarode, R.; Weinberg, I. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions-Part II: Recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J. Vasc. Interv. Radiol. 2019, 30, 1168–1184.e1161. [CrossRef]

113. Samadi, K.; Arellano, R.S. Ureteral protection during microwave ablation of renal cell carcinoma: Combined use of pyeloperfusion and hydrodissection. Diagn. Interv. Radiol. 2015, 24, 388–391. [CrossRef]

114. Tempero, M.A.; Malafa, M.P.; Al-Hawary, M.; Behrman, S.W.; Benson, A.B.; Cardin, D.B.; Chiorean, E.G.; Chung, V.; Czito, B.; Del Chiario, M.; et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2021, 19, 439–457. [CrossRef]

115. Granata, V.; Grassi, R.; Fusco, R.; Setola, S.V.; Palaia, R.; Belli, A.; Miele, V.; Brunese, L.; Grassi, R.; Pettrillo, A.; et al. Assessment of Ablation Therapy in Pancreatic Cancer: The Radiologist’s Challenge. Front. Oncol. 2020, 10, 560952. [CrossRef] [PubMed]

116. Paiella, S.; Salvia, R.; Ramera, M.; Girelli, R.; Frigerio, I.; Giardino, A.; Allegrini, V.; Bassi, C. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review. Gastroenterol. Res. Pract. 2016, 2016, 4508376. [CrossRef] [PubMed]

117. van Veldhuisen, E.; van den Oord, C.; Brada, L.J.H.; van Dam, R.M.; et al. Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers 2019, 11, 976. [CrossRef] [PubMed]

118. Walma, M.S.; Rombouts, S.J.; Brada, L.J.H.; Borel Rinkes, I.H.; Bosscha, K.; Bruijnen, R.C.; Busch, O.R.; Creemers, G.J.; Daams, F.; van Dam, R.M.; et al. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): Study protocol for a randomized controlled trial. Trials 2021, 22, 313. [CrossRef]

119. Rombouts, S.J.; Vogel, J.A.; van Santvoort, H.C.; van Lienden, K.P.; van Hillegersberg, R.; Busch, O.R.; Besselin, M.G.; Molenaar, I.Q. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br. J. Surg. 2015, 102, 182–193. [CrossRef]

120. Narayanan, G.; Doshi, M.H. Ablation for Pancreatic Carcinoma. Endovasc. Today 2015, 14, 96–99.

121. Maiti, D.; Mauri, G.; Varano, G.; Bonomo, G.; Della Vigna, P.; Rebonato, A.; Orsi, F. Percutaneous Ablation: Minimally invasive treatment options. Int. J. Hyperth. 2019, 36, 53–58. [CrossRef]

122. Narayanan, G.; Daye, D.; Wilson, N.M.; Noman, R.; Mahendra, A.M.; Doshi, M.H. Ablation in Pancreatic Cancer: Past, Present and Future. Cancers 2021, 13, 2511. [CrossRef] [PubMed]

123. Donlon, P.; Denny, M.C. Thermal ablation in adrenal disorders: A discussion of the technology, the clinical evidence and the future. Curr. Opin. Endocrinol. Diabetes Obes. 2021, 28, 291–302. [CrossRef]
124. Yamakado, K. Image-guided ablation of adrenal lesions. *Semin. Interv. Radiol.* 2014, 31, 149–156. [CrossRef]

125. Dennyedy, M.C.; Annamalai, A.K.; Prankerd-Smith, O.; Freeman, N.; Vengopal, K.; Graggaber, J.; Koulouri, O.; Powlsion, A.S.; Shaw, A.; Halsall, D.J.; et al. Low DHEAS: A Sensitive and Specific Test for the Detection of Subclinical Hypercortisolism in Adrenal Incidentalomas. *J. Clin. Endocrinol. Metab.* 2017, 102, 786–792. [CrossRef] [PubMed]

126. Shaikh, J.; Raymond, A.; Somasundaram, A.; Loya, M.F.; Nezami, N. Novel Protocol for CT-Guided Percutaneous Ablation of Hyperplastic Adrenal Glands in Cushing Syndrome. *CardioVascular Interv. Radiol.* 2022, 45, 1–12. [CrossRef] [PubMed]

127. Rosiak, G.; Milczarek, K.; Konecki, D.; Otto, M.; Rowinski, O.; Zgliczynski, W. Percutaneous Bilateral Adrenal Radiofrequency Ablation in Severe Adrenocorticotrophic Hormone-dependent Cushing Syndrome. *J. Clin. Imaging Sci.* 2020, 10, 60. [CrossRef] [PubMed]

128. Pan, S.; Baal, J.D.; Chen, W.C.; Baal, U.; Pai, J.S.; Baal, J.H.; Zagoria, R. Image-Guided Percutaneous Ablation of Adrenal Metastases: A Meta-Analysis of Efficacy and Safety. *J. Vasc. Interv. Radiol.* 2021, 32, 527–535.e521. [CrossRef]

129. Kohlenberg, J.; Welch, B.; Hamidi, O.; Callstrom, M.; Morris, J.; Sprung, J.; Bancos, I.; Young, W., Jr. Efficacy and Safety of Ablative Therapy in Patients with Metastatic Pheochromocytoma and Paraganglioma. *Cancers* 2019, 11, 195. [CrossRef] [PubMed]

130. Venkatesan, A.M.; Locklin, J.; Dupuy, D.E.; Wood, B.J. Percutaneous ablation of adrenal tumors. *Tech. Vasc. Interv. Radiol.* 2010, 13, 89–99. [CrossRef]

131. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016, 26, 1–153. [CrossRef]

132. Spiezia, S.; Garberoglio, R.; Milone, F.; Ramundo, V.; Caiazzo, C.; Assanti, A.P.; Deandra, M.; Limone, P.P.; Macchia, P.E.; Lombardi, G.; et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. *Thyroid* 2009, 19, 219–225. [CrossRef]

133. Huh, J.Y.; Baek, J.H.; Choi, H.; Kim, J.K.; Lee, J.H. Symptomatic benign thyroid nodules: Efficacy of additional radiofrequency ablation treatment session—Prospective randomized study. *Radiology* 2012, 263, 909–916. [CrossRef]

134. Bernardi, S.; Dobrinja, C.; Fabris, B.; Bazzocchi, G.; Sabato, N.; Ulcigrai, V.; Giacca, M.; Barro, E.; De Manzini, N.; Stacul, F. Radiofrequency ablation compared to surgery for the treatment of benign thyroid nodules. *Int. J. Endocrinol.* 2014, 2014, 934959. [CrossRef]

135. Trimboli, P.; Castellana, M.; Sconfienza, L.M.; Virili, C.; Pescatori, L.C.; Cesareo, R.; Giorgino, F.; Negro, R.; Giovanella, L.; Mauri, G. Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: A systematic review and meta-analysis. *Endocrine* 2020, 67, 35–43. [CrossRef] [PubMed]

136. Kim, J.H.; Yoo, W.S.; Park, Y.J.; Park, D.J.; Yun, T.J.; Choi, S.H.; Sohn, C.H.; Lee, K.E.; Sung, M.W.; Youn, Y.K.; et al. Efficacy and Safety of Radiofrequency Ablation for Treatment of Locally Recurrent Thyroid Cancers Smaller than 2 cm. *Radiology* 2015, 276, 909–918. [CrossRef] [PubMed]

137. Chung, S.R.; Baek, J.H.; Choi, Y.J.; Lee, J.H. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. *Eur. Radiol.* 2019, 29, 4897–4903. [CrossRef] [PubMed]

138. Choi, Y.; Jung, S.L.; Bae, J.S.; Lee, S.H.; Jung, C.K.; Jang, J.; Shin, N.Y.; Choi, H.S.; Ahn, K.J.; Kim, B.S. Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: A single-center propensity score matching study. *Int. J. Hyperth.* 2019, 36, 359–367. [CrossRef]

139. Lim, H.K.; Baek, J.H.; Lee, J.H.; Kim, W.B.; Kim, Y.T.; Shong, Y.K.; Hong, S.J. Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer. *Eur. Radiol.* 2015, 25, 163–170. [CrossRef]

140. Li, J.; Liu, Y.; Liu, J.; Yang, P.; Hu, X.; Qian, L. A comparative study of short-term efficacy and safety for thyroid micropapillary carcinoma patients after microwave ablation or surgery. *Int. J. Hyperth.* 2019, 36, 640–646. [CrossRef]

141. Gong, L.; Tang, W.; Lu, J.; Xu, W. Thermal ablation versus parathyroidectomy for secondary hyperparathyroidism: A meta-analysis. *Int. J. Surg.* 2019, 70, 13–18. [CrossRef]

142. Ye, J.; Huang, W.; Huang, G.; Qiu, Y.; Peng, W.; Lan, N.; Xie, X.; Liu, B. Efficacy and safety of US-guided thermal ablation for primary hyperparathyroidism: A systematic review and meta-analysis. *Int. J. Hyperth.* 2020, 37, 245–253. [CrossRef]

143. Cao, X.J.; Zhao, Z.L.; Wei, Y.; Peng, L.L.; Li, Y.; Yu, M.A. Efficacy and safety of microwave ablation treatment for secondary hyperparathyroidism: Systematic review and meta-analysis. *Int. J. Hyperth.* 2020, 37, 316–323. [CrossRef]

144. Zhou, X.; Shen, Y.; Zhu, Y.; Lv, Q.; Pu, W.; Gao, L.; Gu, M.; Li, C. Ultrasound-guided microwave ablation for secondary hyperparathyroidism: A systematic review and meta-analysis. *Int. J. Hyperth.* 2021, 38, 1285–1294. [CrossRef]

145. Erturk, M.S.; Cekic, B.; Sari, I.K.; Pamuk, B.O. Microwave ablation as an efficient therapy for primary hyperparathyroidism: Efficacy and predictors of treatment success. *Int. J. Clin. Pract.* 2021, 75, e14580. [CrossRef] [PubMed]

146. Guo, D.M.; Chen, Z.; Zhai, Y.X.; Su, H.H. Comparison of radiofrequency ablation and microwave ablation for benign thyroid nodules: A systematic review and meta-analysis. *Clin. Endocrinol.* 2021, 95, 187–196. [CrossRef] [PubMed]

147. He, L.; Zhao, W.; Xia, Z.; Su, A.; Li, Z.; Zhu, J. Comparative efficacy of different ultrasound-guided ablation for the treatment of benign thyroid nodules: Systematic review and network meta-analysis of randomized controlled trials. *PLoS ONE* 2021, 16, e0243864. [CrossRef]
197. Deib, G.; Deldar, B.; Hui, F.; Barr, J.S.; Khan, M.A. Percutaneous Microwave Ablation and Cementoplasty: Clinical Utility in the Treatment of Painful Extraspinal Osseous Metastatic Disease and Myeloma. AJR Am. J. Roentgenol. 2019, 212, 1377–1384. [CrossRef] [PubMed]

198. Cazzato, R.L.; Palussière, J.; Auloge, P.; Rousseau, C.; Koch, G.; Dalili, D.; Buy, X.; Gannon, J.; De Marini, P.; Gangi, A. Complications Following Percutaneous Image-guided Radiofrequency Ablation of Bone Tumors: A 10-year Dual-Center Experience. Radiology 2020, 296, 227–235. [CrossRef] [PubMed]

199. Kurup, A.N.; Schmit, G.D.; Morris, J.M.; Atwell, T.D.; Schmitz, J.J.; Weibrod, A.J.; Woodrum, D.A.; Eiken, P.W.; Callstrom, M.R. Avoiding Complications in Bone and Soft Tissue Ablation. Cardiovasc. Intern. Radiol. 2017, 40, 166–176. [CrossRef]

200. Foster, R.C.; Stavas, J.M. Bone and soft tissue ablation. Semin. Interv. Radiol. 2014, 31, 167–179. [CrossRef]

201. Kurtz, J.E.; Buy, X.; Deschamps, F.; Sauleau, E.; Bouhamama, A.; Toulmonde, M.; Honoré, C.; Bertucci, F.; Brahmi, M.; Chevreau, C.; et al. CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur. J. Cancer 2021, 143, 78–87. [CrossRef]

202. Thompson, S.M.; Callstrom, M.R.; McKusick, M.A.; Woodrum, D.A. Initial Results of Image-Guided Percutaneous Ablation as Second-Line Treatment for Symptomatic Vascular Anomalies. Cardiovasc. Intern. Radiol. 2015, 38, 1171–1178. [CrossRef]

203. Lane, M.D.; Le, H.B.; Lee, S.; Young, C.; Heran, M.K.; Badii, M.; Clarkson, P.W.; Munk, P.L. Combination radiofrequency ablation and cementoplasty for palliative treatment of painful neoplastic bone metastasis: Experience with 53 treated lesions in 36 patients. Skelet. Radiol. 2011, 40, 25–32. [CrossRef]

204. de Baere, T.; Tsilikas, L.; Gravel, G.; Hakime, A.; Deschamps, F.; Honoré, C.; Mir, O.; Lecesne, A. Interventional radiology: Role in the treatment of sarcomas. Eur. J. Cancer 2018, 94, 148–155. [CrossRef]

205. Nakamura, T.; Matsumine, A.; Yamakado, K.; Matsubara, T.; Takaki, H.; Nakatsuka, A.; Takeda, K.; Abo, D.; Shimizu, T.; Uchida, A. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas. Cancer 2009, 115, 3774–3781. [CrossRef] [PubMed]

206. Sato, T.; Iguchi, T.; Hiraki, T.; Gobara, H.; Fujiwara, H.; Sakurai, J.; Matsui, Y.; Mitsuhashi, T.; Koh, J.; Toyooka, S.; et al. Radiofrequency ablation of pulmonary metastases from sarcoma: Single-center retrospective evaluation of 46 patients. Jpn. J. Radiol. 2017, 35, 61–67. [CrossRef] [PubMed]

207. Palussière, J.; Italiano, A.; Descat, E.; Ferron, S.; Cornélis, F.; Avril, A.; Brousté, V.; Bui, B.N. Sarcoma lung metastases treated with percutaneous radiofrequency ablation: Results from 29 patients. Ann. Surg. Oncol. 2011, 18, 3771–3777. [CrossRef] [PubMed]

208. Grilley-Olson, J.E.; Webber, N.P.; Demos, D.S.; Christensen, J.D.; Kirsch, D.G. Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 939–948. [CrossRef] [PubMed]

209. Ghanouni, P.; Dobrotwir, A.; Bazzocchi, A.; Bucknor, M.; Bitton, R.; Rosenbarg, J.; Telischak, K.; Busacca, M.; Ferrari, S.; Albisinni, U.; et al. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: A retrospective multicenter study. Eur. Radiol. 2017, 27, 732–740. [CrossRef]